Class / Patent application number | Description | Number of patent applications / Date published |
552557000 | Carbon bonded directly at the 17-beta-position of the cyclopentanohydrophenanthrene ring system is a member of an acyclic chain of two uninterrupted carbons (e.g., pregnanes, etc.) | 13 |
552559000 | Three or more oxygens bonded directly to the cyclopentanohydrophenanthrene ring system | 3 |
552562000 | Oxygen bonded directly at the 7-, 8- or 9-position | 1 |
20160083415 | Crystalline Anhydrate Forms Of A Pharmaceutical - The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions. | 03-24-2016 |
552569000 | Oxygen bonded directly at the 3-, 11-, and 17-positions | 2 |
552580000 | Carbon or halogen bonded directly at the 6- or 7-position | 2 |
20100130760 | PROCESS FOR PREPARING A CRYSTALLINE FORM OF HALOBETASOL PROPIONATE - The present invention provides a process for preparing a crystalline form of halobetasol propionate, comprising the step of crystallizing halobetasol propionate from absolute ethanol or a mixture of ethanol and water, wherein the crystalline form of halobetasol propionate is characterized by an x-ray powder diffraction pattern having peaks at 10.0, 11.6, 12.9, 13.4, 14.5, 16.4, 17.6, and 23.5±0.2 degrees 2θ. | 05-27-2010 |
20130217903 | PROCESS FOR PREPARING A CRYSTALLINE FORM OF HALOBETASOL PROPIONATE - The present invention provides a process for preparing a crystalline form of halobetasol propionate, comprising the step of crystallizing halobetasol propionate from absolute ethanol or a mixture of ethanol and water, wherein the crystalline form of halobetasol propionate is characterized by an x-ray powder diffraction pattern having peaks at 10.0, 11.6, 12.9, 13.4, 14.5, 16.4, 17.6, and 23.5±0.2 degrees 2θ. | 08-22-2013 |
552582000 | Two oxygens bonded directly to the cyclopentanohydrophenanthrene ring system | 7 |
552592000 | Oxygen bonded directly at the 3- and 17-positions | 7 |
20090318720 | Process for selectively synthesising 3 alpha-hydroxychlormadinone acetate - The invention relates to a process for synthesising 3α-hydroxychlormadinone acetate. | 12-24-2009 |
552593000 | Oxygen bonded directly at the 21-position | 2 |
552595000 | Unsaturation between the 4- and 5-positions (e.g., 17-alpha-hydroxy progesterones, etc.) | 2 |
20100041906 | METHOD FOR THE PRECIPITATION OF ORGANIC COMPOUNDS - The present invention concerns a method for the controlled precipitation of organic compounds giving crystals with a very small average size and a very narrow size distribution. | 02-18-2010 |
20110237811 | STABILIZED STEROID COMPOSITION AND METHOD FOR ITS PREPARATION - Stabilized, 17-substituted hydrocortisone containing compositions and methods of manufacture are disclosed. Isomerization of the hydrocortisone component of topical steroid compositions is markedly reduced by including an omega-6 acid component in the form of a free acid or as a compound such as an ester. Specifically disclosed are methods for preventing the isomerization of hydrocortisone 17-butyrate into hydrocortisone 21-butyrate through the use of safflower oil. | 09-29-2011 |
552597000 | Carbon or halogen bonded directly at the 6- or 7-position | 1 |
20100204497 | Process For The Preparation of 7 alpha-Methylsteroids - The invention relates to a process for the preparation of 7α-methyl hydroxy steroids of the formula I | 08-12-2010 |
552598000 | Unsaturation between the 4- and 5-positions | 3 |
20090012321 | PROCESS FOR PREPARING 17ALPHA-ACETOXY-6-METHYLENEPREGN-4-ENE-3,20-DIONE, MEDROXYPROGESTERONE ACETATE AND MEGESTROL ACETATE - The present invention relates to a process for preparing 17α-acetoxy-6-methylenepregn-4-ene-3,20-dione (4) as an intermediate, and to processes for preparing medroxyprogesterone acetate (1) (17α-acetoxy-6α-methylpregn-4-ene-3,20-dione) and megestrol acetate (2) (17α-acetoxy-6-methylpregna-4,6-diene-3,20-dione) via this intermediate (4). | 01-08-2009 |
20090069584 | Levonorgestrel Crystallization - The present invention provides for a crystalline polymorph of levonorgestrel and processes for making the same. | 03-12-2009 |
20100298585 | METHOD FOR SYNTHESIS OF DIENOGEST FROM ESTRONE-3-METHYLETHER - A method for the synthesis of dienogest from 3-methoxy-estra-1,3,5-trien-17-one includes the steps of a) reacting 3-methoxy-estra-1,3,5-trien-17-one with alcohol in the presence of an acid in an organic solvent to form 3-methoxy-17,17-dialkoxy-estra-1,3,5-triene; b) subjecting the product of step a) to partial reduction by reaction with alkali metal in liquid ammonia; c) treating the product of step b) with mild acid; d) reacting the product of step c) with cyanomethyl lithium; e) treating the product of step d) with oxalic acid; and f) treating the product of step e) with pyridinium tribromide in pyridine to yield dienogest. | 11-25-2010 |
552599000 | Exactly one oxygen bonded directly to the cyclopentanohydrophenanthrene ring system | 3 |
552600000 | Oxygen bonded directly at the 21-position | 1 |
552601000 | Unsaturation between the 4- and 5-position (e.g., desoxycorticosterones, etc.) | 1 |
552602000 | Additional unsaturation in the cyclopentanohydrophenanthrene ring system | 1 |
20080234506 | PROCESS FOR THE PREPARATION OF FLUOROTETRAENE - There is provided a process for preparing 21-acetyloxy-6-alpha-fluoro-pregna-1,4,9(11),16-tetraene-3,20-dione compound of Formula I, which comprises reacting 21-acetyloxy-pregna-1,3,5,9(11),16-pentaene-3-oxo acetate with a fluorinating agent. | 09-25-2008 |
552603000 | Carbon or halogen bonded directly at the 1-, 2-, 3-, 4- or 5-position | 1 |
20110040112 | METHOD FOR MAKING 3A-HYDROXY, 3B- SUBSTITUTED-5A-PREGNAN-20-ONES - Applicants have discovered a method for the stereoselective and regioselective synthesis of 3α-hydroxy, 3β-methyl-5α-pregnan-20-one (ganaxolone) comprising reacting 5α-pregnane-3,20-dione; with an organometallic methylating agent in an inert solvent to provide a compound of the formula | 02-17-2011 |
552607000 | Unsaturation between the 4- and 5-positions (e.g., progesterones, etc.) | 1 |
20160108081 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF - The present invention relates to the synthesis of ent-progesterone and intermediates thereof. | 04-21-2016 |